Tonix Pharmaceuticals presents results from nonclinical cyclobenzapri studies

Tonix Pharmaceuticals presented results from nonclinical studies of cyclobenzaprine, the active ingredient of Tonix's lead candidate, TNX-102 sublingual tablet, at the International Pain Society's Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome. "We believe TNX-102 SL exerts pharmacological effects distinct from those exerted by products approved by the FDA for the management of fibromyalgia and PTSD. We look forward to commencing our Phase 2b,3 trial of TNX-102 SL in patients with fibromyalgia this quarter," said Doctor Bruce Daugherty, Tonix's Chief Scientific Officer.


View Comments (0)